Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies

Shashi Gujar; Jonathan G. Pol; Guido Kroemer

doi:10.1080/2162402X.2018.1442169

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies

Shashi Gujar, Jonathan G. Pol, Guido Kroemer

Medicine

Research output: Contribution to journal › Editorial › peer-review

96 Citations (Scopus)

Abstract

Immune checkpoint blockade is less efficient in patients bearing immunologically ‘cold’ tumors. Oncolytic viruses, which were originally discovered for their ability to preferentially kill malignant cells, can recondition the tumor microenvironment. Supporting this hypothesis, two new studies published in Science Translational Medicine show that adjuvant-like activities of oncolytic viruses make brain and breast tumors ‘hot’ and sensitize them for subsequent immune checkpoint blockade.

Original language	English
Article number	e1442169
Journal	OncoImmunology
Volume	7
Issue number	8
DOIs	https://doi.org/10.1080/2162402X.2018.1442169
Publication status	Published - Aug 3 2018

Bibliographical note

Funding Information:
SG is supported by grants from the Canadian Institutes of Health Research (CIHR) and Beatrice Hunter Cancer Research Institute (BHCRI). GK’s team is supported by the Ligue contre le Cancer Comitéde Charente-Maritime (équipe labelisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Can-céropôle Ile-de-France; Chancellerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; the European Commission (ArtForce); European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).

Funding Information:
SG is supported by grants from the Canadian Institutes of Health Research (CIHR) and Beatrice Hunter Cancer Research Institute (BHCRI). GK's team is supported by the Ligue contre le Cancer Comit? de Charente-Maritime (?quipe labelis?e); Agence National de la Recherche (ANR)?Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc?rop?le Ile-de-France; Chancellerie des universit?s de Paris (Legs Poix), Fondation pour la Recherche M?dicale (FRM); a donation by Elior; the European Commission (ArtForce); European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumi?re; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).

Publisher Copyright:
© 2018, © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC. © 2018, © Shashi Gujar, Jonathan G. Pol and Guido Kroemer.

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.1080/2162402X.2018.1442169

Cite this

@article{363034c63ca74513ad05cf022f2889c4,

title = "Heating it up: Oncolytic viruses make tumors {\textquoteleft}hot{\textquoteright} and suitable for checkpoint blockade immunotherapies",

abstract = "Immune checkpoint blockade is less efficient in patients bearing immunologically {\textquoteleft}cold{\textquoteright} tumors. Oncolytic viruses, which were originally discovered for their ability to preferentially kill malignant cells, can recondition the tumor microenvironment. Supporting this hypothesis, two new studies published in Science Translational Medicine show that adjuvant-like activities of oncolytic viruses make brain and breast tumors {\textquoteleft}hot{\textquoteright} and sensitize them for subsequent immune checkpoint blockade.",

author = "Shashi Gujar and Pol, {Jonathan G.} and Guido Kroemer",

note = "Funding Information: SG is supported by grants from the Canadian Institutes of Health Research (CIHR) and Beatrice Hunter Cancer Research Institute (BHCRI). GK{\textquoteright}s team is supported by the Ligue contre le Cancer Comit{\'e}de Charente-Maritime ({\'e}quipe labelis{\'e}e); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Can-c{\'e}rop{\^o}le Ile-de-France; Chancellerie des universit{\'e}s de Paris (Legs Poix), Fondation pour la Recherche M{\'e}dicale (FRM); a donation by Elior; the European Commission (ArtForce); European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumi{\`e}re; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Funding Information: SG is supported by grants from the Canadian Institutes of Health Research (CIHR) and Beatrice Hunter Cancer Research Institute (BHCRI). GK's team is supported by the Ligue contre le Cancer Comit? de Charente-Maritime (?quipe labelis?e); Agence National de la Recherche (ANR)?Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc?rop?le Ile-de-France; Chancellerie des universit?s de Paris (Legs Poix), Fondation pour la Recherche M?dicale (FRM); a donation by Elior; the European Commission (ArtForce); European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumi?re; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 The Author(s). Published with license by Taylor & Francis Group, LLC. {\textcopyright} 2018, {\textcopyright} Shashi Gujar, Jonathan G. Pol and Guido Kroemer.",

year = "2018",

month = aug,

day = "3",

doi = "10.1080/2162402X.2018.1442169",

language = "English",

volume = "7",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "8",

}

TY - JOUR

T1 - Heating it up

T2 - Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies

AU - Gujar, Shashi

AU - Pol, Jonathan G.

AU - Kroemer, Guido

N1 - Funding Information: SG is supported by grants from the Canadian Institutes of Health Research (CIHR) and Beatrice Hunter Cancer Research Institute (BHCRI). GK’s team is supported by the Ligue contre le Cancer Comitéde Charente-Maritime (équipe labelisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Can-céropôle Ile-de-France; Chancellerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; the European Commission (ArtForce); European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Funding Information: SG is supported by grants from the Canadian Institutes of Health Research (CIHR) and Beatrice Hunter Cancer Research Institute (BHCRI). GK's team is supported by the Ligue contre le Cancer Comit? de Charente-Maritime (?quipe labelis?e); Agence National de la Recherche (ANR)?Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc?rop?le Ile-de-France; Chancellerie des universit?s de Paris (Legs Poix), Fondation pour la Recherche M?dicale (FRM); a donation by Elior; the European Commission (ArtForce); European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumi?re; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Publisher Copyright: © 2018, © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC. © 2018, © Shashi Gujar, Jonathan G. Pol and Guido Kroemer.

PY - 2018/8/3

Y1 - 2018/8/3

N2 - Immune checkpoint blockade is less efficient in patients bearing immunologically ‘cold’ tumors. Oncolytic viruses, which were originally discovered for their ability to preferentially kill malignant cells, can recondition the tumor microenvironment. Supporting this hypothesis, two new studies published in Science Translational Medicine show that adjuvant-like activities of oncolytic viruses make brain and breast tumors ‘hot’ and sensitize them for subsequent immune checkpoint blockade.

AB - Immune checkpoint blockade is less efficient in patients bearing immunologically ‘cold’ tumors. Oncolytic viruses, which were originally discovered for their ability to preferentially kill malignant cells, can recondition the tumor microenvironment. Supporting this hypothesis, two new studies published in Science Translational Medicine show that adjuvant-like activities of oncolytic viruses make brain and breast tumors ‘hot’ and sensitize them for subsequent immune checkpoint blockade.

UR - http://www.scopus.com/inward/record.url?scp=85043720630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043720630&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1442169

DO - 10.1080/2162402X.2018.1442169

M3 - Editorial

C2 - 30221036

AN - SCOPUS:85043720630

SN - 2162-4011

VL - 7

JO - OncoImmunology

JF - OncoImmunology

IS - 8

M1 - e1442169

ER -

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this